WO2000052034A3 - Inhibiteurs d'activite de serine protease, methodes et compositions de traitement d'infections virales - Google Patents

Inhibiteurs d'activite de serine protease, methodes et compositions de traitement d'infections virales Download PDF

Info

Publication number
WO2000052034A3
WO2000052034A3 PCT/US2000/005558 US0005558W WO0052034A3 WO 2000052034 A3 WO2000052034 A3 WO 2000052034A3 US 0005558 W US0005558 W US 0005558W WO 0052034 A3 WO0052034 A3 WO 0052034A3
Authority
WO
WIPO (PCT)
Prior art keywords
serine protease
infection
viral infections
inhibitors
compositions
Prior art date
Application number
PCT/US2000/005558
Other languages
English (en)
Other versions
WO2000052034A2 (fr
Inventor
Leland Shapiro
Original Assignee
Trustees Of University Technol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of University Technol filed Critical Trustees Of University Technol
Priority to AU37191/00A priority Critical patent/AU3719100A/en
Publication of WO2000052034A2 publication Critical patent/WO2000052034A2/fr
Publication of WO2000052034A3 publication Critical patent/WO2000052034A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une nouvelle méthode de traitement et de prévention d'une infection virale. L'invention concerne, en particulier, une méthode destinée à combattre une infection virale favorisée par une activité de sérine protéolytique (SP), consistant à administrer à un sujet souffrant ou susceptible de souffrir d'une infection virale une quantité thérapeutiquement efficace d'un composé présentant une activité d'inhibition de sérine protéase ou serpin. Parmi les composés se trouvent l'antitrypsine α1 (AAT), des dérivés peptidiques de l'extrémité carboxyterminale de l'AAT, et des composés synthétiques artificiels imitant l'action de ces composés. Parmi les infections virales préférées se trouvent les infections rétrovirales telles que l'infection du virus de l'immunodéficience humaine (VIH).
PCT/US2000/005558 1999-03-05 2000-03-03 Inhibiteurs d'activite de serine protease, methodes et compositions de traitement d'infections virales WO2000052034A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37191/00A AU3719100A (en) 1999-03-05 2000-03-03 Inhibitors of serine protease activity, methods and compositions for treatment of viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12316799P 1999-03-05 1999-03-05
US60/123,167 1999-03-05
US13779599P 1999-06-03 1999-06-03
US60/137,795 1999-06-03

Publications (2)

Publication Number Publication Date
WO2000052034A2 WO2000052034A2 (fr) 2000-09-08
WO2000052034A3 true WO2000052034A3 (fr) 2001-01-11

Family

ID=26821301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005558 WO2000052034A2 (fr) 1999-03-05 2000-03-03 Inhibiteurs d'activite de serine protease, methodes et compositions de traitement d'infections virales

Country Status (2)

Country Link
AU (1) AU3719100A (fr)
WO (1) WO2000052034A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849605B1 (en) 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
US8563693B2 (en) 2001-01-26 2013-10-22 Acceleration Biopharmaceuticals, Inc. Method of treating human immunodeficiency virus infection in a mammal comprising administering heparin-activated antithrombin III
ATE377657T1 (de) * 2001-01-26 2007-11-15 Gen Hospital Corp Serpin-arzneistoffe zur behandlung einer hiv- infektion und verfahren zu deren verwendung
CA2536918A1 (fr) 2003-08-26 2005-03-03 Leland Shapiro Compositions et procedes pour molecules de fusion fc de l'alpha-1 antitrypsine
WO2007079312A2 (fr) * 2005-12-02 2007-07-12 Regents Of The University Of Colorado Compositions et procédés de traitement d’affections pathologiques médiées par l'actine
ES2535704T3 (es) 2010-09-14 2015-05-14 F. Hoffmann-La Roche Ag Polipéptido de fusión serpina-dedo
CA2839917A1 (fr) 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, procedes et utilisations de molecules de fusion de l'alpha-1 antitrypsine
JP2015504675A (ja) 2012-01-10 2015-02-16 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ アルファ−１アンチトリプシン融合分子の組成物、方法、及び使用
WO2014031784A1 (fr) 2012-08-23 2014-02-27 Alios Biopharma, Inc. Composés pour le traitement d'infections virales par paramyxovirus
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532215A (en) * 1992-09-30 1996-07-02 Lezdey; John Antiviral compositions and method of use
WO1998024806A2 (fr) * 1996-12-06 1998-06-11 Cortech, Inc. Inhibiteurs de la serine protease
WO1998046597A1 (fr) * 1997-04-14 1998-10-22 Emory University Inhibiteurs de serines proteases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532215A (en) * 1992-09-30 1996-07-02 Lezdey; John Antiviral compositions and method of use
WO1998024806A2 (fr) * 1996-12-06 1998-06-11 Cortech, Inc. Inhibiteurs de la serine protease
WO1998046597A1 (fr) * 1997-04-14 1998-10-22 Emory University Inhibiteurs de serines proteases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDERSON ERIC D ET AL: "Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha-1-antitrypsin variant.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 33, 1993, pages 24887 - 24891, XP002145342, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
AU3719100A (en) 2000-09-21
WO2000052034A2 (fr) 2000-09-08

Similar Documents

Publication Publication Date Title
WO2000051623A3 (fr) Inhibiteurs d'activite de serine protease, methodes et compositions de traitement des etats cliniques dus au bioxyde d'azote
NO983688L (no) Serin-protease-inhibitorer
FI912328A0 (fi) Peptidfoerening och dess framstaellning.
EA199700221A1 (ru) Замещенный аминокислотой гидроксиэтиламиносульфонамид в качестве ингибиторов ретровирусной протеазы
GEP20012415B (en) THF-Containing Sulfonamide Inhibitors of Aspartyl Protease
NO20075806L (no) Aminosyrehydroksyetylaminosulfonamid retrovirale proteaseinhibitorer
DE69531944D1 (de) Neue hiv-protease-inhibitoren
PL322169A1 (en) Sulphonylalkanoylamino hydroxyethylaminosulphonamides as inhibitors of retroviral protease
WO2000052034A3 (fr) Inhibiteurs d'activite de serine protease, methodes et compositions de traitement d'infections virales
NO974147L (no) Heterocykelkarbonylaminosyre hydroksyetylaminosulfonamid retroviral protease
NO983992L (no) Serinprotease inhibitorer
NO983991L (no) Serin-protease-inhibitorer
MD960172A (en) 5,6-dihydropyrone derivatives as proteaze inhibitors and antiviral agents
DK1053012T3 (da) Farmaceutiske sammensætninger omfattende PEG-asparaginase til behandling af HIV-infektioner
WO2001010454A3 (fr) Composition et procedes de traitement d'infection par le vih
NZ256246A (en) Serine leukocyte protease inhibitor, recombinant preparation thereof, and treatment of a retroviral infection
WO2000027418A3 (fr) Traitement de tissus ischemiquement degrades

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase